Lupin to Acquire Majority Stake in Multicare Pharma

Lupin's Subsidiary to Acquire Minority Stake in Multicare Pharmaceuticals Philippines, Inc.

Lupin shares will remain in focus on April 2 after the company announced that its subsidiary, Nanomi B.V., Netherlands, has entered into definitive agreements to acquire a minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI). In an exchange filing, the company stated that Nanomi will acquire 11,794,497 shares, representing a 43.38% stake, in MPPI from existing shareholders. The acquisition is valued at up to $39.6 million and is expected to be completed by the end of May 2026, subject to closing conditions.

In a separate development, Lupin informed that Nanomi has completed the full acquisition of VISUfarma B.V., Netherlands. Consequently, VISUfarma and its subsidiaries have become wholly owned subsidiaries of Nanomi effective April 1, 2026. This acquisition marks a significant milestone in Lupin's expansion strategy.

Lupin has been making strides in strengthening its pipeline, with the company receiving tentative approvals from the US Food and Drug Administration (USFDA) for Sugammadex Injection and Pitolisant Tablets last month. The Pitolisant tablets will be manufactured at the company's Nagpur facility. This development is expected to have a positive impact on the company's future growth prospects.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

In the previous trading session, the stock closed at ₹2,273.60, down ₹39.10 or 1.69%. The stock has touched a 52-week high of ₹2,376 and a low of ₹1,774. It is currently trading 4.31% below its 52-week high and 28.16% above its 52-week low.

| Comparison of Lupin's 52-Week High and Low | | --- | --- | | 52-Week High | ₹2,376 | | 52-Week Low | ₹1,774 | | Current Price | ₹2,273.60 | | Percentage Below 52-Week High | 4.31% | | Percentage Above 52-Week Low | 28.16% |

The company's market capitalisation stands at ₹1.04 lakh crore.